Literature DB >> 27921232

Biological function and mechanism of miR-33a in prostate cancer survival and metastasis: via downregulating Engrailed-2.

Q Li1, S Lu2, X Li3, G Hou4, L Yan2, W Zhang2, B Qiao2.   

Abstract

OBJECTIVE: Recent studies have identified Engrailed-2 (EN-2), a homeobox-containing transcription factor, as a candidate oncogene in prostate cancer (PC). Therapeutic targeting on EN-2, however, is limited because the mechanism underlying EN-2 overexpression in prostatic cancer cells is unknown. This study was to investigate the potential regulatory role of miR-33a on EN-2 expression and explore this signaling axis in ability of prostate cancer survival and metastasis.
METHODS: The relative expression of miR-33a and EN-2 in paired prostate cancer tissue and adjacent normal tissue as well as in prostate cancer cell lines, PC3 and DU145, was determined using quantitative real-time PCR or western blot, respectively. Cells survival, migration and invasion were evaluated by assays of MTT, TUNEL and Boyden chamber assays, respectively. Direct regulation of EN-2 by miR-33a was examined by luciferase reporter assay.
RESULTS: The data showed that miR-33a was upregulated and EN-2 was downregulated in both prostate cancer tissue and prostate cancer cells. miR-33a overexpression suppresses prostate cancer cell survival and metastasis. miR-33a can directly act on EN-2 expression by binding to 3'UTR of its mRNA. Also, miR-33a negatively regulated EN-2 mRNA and protein expression. In pcDNA-EN-2 and miR-33a mimic co-transfected PC3 and DU145 cells, EN-2 overexpression reverses the anti-cell survival and metastasis actions of miR-33a overexpression. The pivotal role of miR-33a in inhibiting prostate tumor growth was confirmed in xenograft models of prostate cancer.
CONCLUSION: Our data suggest that the functional interaction of miR-33a and EN-2 is involved in tumorigenesis of prostate cancer. Also in this process EN-2 serves as a negative responder for miR-33a.

Entities:  

Keywords:  Engrailed-2; MiR-33a; Migration; Prostate cancer

Mesh:

Substances:

Year:  2016        PMID: 27921232     DOI: 10.1007/s12094-016-1564-3

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  28 in total

1.  Repression of engrailed 2 inhibits the proliferation and invasion of human bladder cancer in vitro and in vivo.

Authors:  Yunfei Li; Haitao Liu; Caiyong Lai; Zexuan Su; Baoli Heng; Shuangquan Gao
Journal:  Oncol Rep       Date:  2015-03-17       Impact factor: 3.906

Review 2.  Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis.

Authors:  Robert R Langley; Isaiah J Fidler
Journal:  Endocr Rev       Date:  2007-04-04       Impact factor: 19.871

3.  MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma.

Authors:  Ahmed Fawzy Ibrahim; Ulrike Weirauch; Maren Thomas; Arnold Grünweller; Roland K Hartmann; Achim Aigner
Journal:  Cancer Res       Date:  2011-06-20       Impact factor: 12.701

4.  Ultrasensitive electrochemical detection of engrailed-2 based on homeodomain-specific DNA probe recognition for the diagnosis of prostate cancer.

Authors:  Seonghwan Lee; Hunho Jo; Jin Her; Ho Yong Lee; Changill Ban
Journal:  Biosens Bioelectron       Date:  2014-11-06       Impact factor: 10.618

Review 5.  Epigenetics in cancer.

Authors:  Shikhar Sharma; Theresa K Kelly; Peter A Jones
Journal:  Carcinogenesis       Date:  2009-09-13       Impact factor: 4.944

6.  Engrailed-2 protein as a potential urinary prostate cancer biomarker: a comparison study before and after digital rectal examination.

Authors:  Michał Piotr Marszałł; Wiktor Sroka; Marek Adamowski; Piotr Słupski; Piotr Jarzemski; Joanna Siódmiak; Grażyna Odrowąż-Sypniewska
Journal:  Eur J Cancer Prev       Date:  2015-01       Impact factor: 2.497

7.  MiR-33a suppresses breast cancer cell proliferation and metastasis by targeting ADAM9 and ROS1.

Authors:  Chuankai Zhang; Yunda Zhang; Weiji Ding; Yancheng Lin; Zhengjie Huang; Qi Luo
Journal:  Protein Cell       Date:  2015-10-27       Impact factor: 14.870

8.  miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST.

Authors:  Yong Zhou; Zufa Huang; Song Wu; Xiaofang Zang; Min Liu; Jian Shi
Journal:  J Exp Clin Cancer Res       Date:  2014-01-27

9.  Regulation of E3 ubiquitin ligase-1 (WWP1) by microRNA-452 inhibits cancer cell migration and invasion in prostate cancer.

Authors:  Yusuke Goto; Satoko Kojima; Akira Kurozumi; Mayuko Kato; Atsushi Okato; Ryosuke Matsushita; Tomohiko Ichikawa; Naohiko Seki
Journal:  Br J Cancer       Date:  2016-04-12       Impact factor: 7.640

Review 10.  Prostate cancer epigenetics and its clinical implications.

Authors:  Srinivasan Yegnasubramanian
Journal:  Asian J Androl       Date:  2016 Jul-Aug       Impact factor: 3.285

View more
  4 in total

1.  Role of germline variants in the metastasis of breast carcinomas.

Authors:  Ángela Santonja; Aurelio A Moya-García; Nuria Ribelles; Begoña Jiménez-Rodríguez; Bella Pajares; Cristina E Fernández-De Sousa; Elísabeth Pérez-Ruiz; María Del Monte-Millán; Manuel Ruiz-Borrego; Juan de la Haba; Pedro Sánchez-Rovira; Atocha Romero; Anna González-Neira; Ana Lluch; Emilio Alba
Journal:  Oncotarget       Date:  2022-06-30

2.  MiR-130b/TNF-α/NF-κB/VEGFA loop inhibits prostate cancer angiogenesis.

Authors:  H Q Mu; Y H He; S B Wang; S Yang; Y J Wang; C J Nan; Y F Bao; Q P Xie; Y H Chen
Journal:  Clin Transl Oncol       Date:  2019-10-30       Impact factor: 3.405

Review 3.  The potential of microRNAs as human prostate cancer biomarkers: A meta-analysis of related studies.

Authors:  Chun-Jiao Song; Huan Chen; Li-Zhong Chen; Guo-Mei Ru; Jian-Jun Guo; Qian-Nan Ding
Journal:  J Cell Biochem       Date:  2017-12-04       Impact factor: 4.429

4.  Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-β signaling.

Authors:  Yuhu Dai; Zhengquan Wu; Chuandong Lang; Xin Zhang; Shaofu He; Qing Yang; Wei Guo; Yingrong Lai; Hong Du; Xinsheng Peng; Dong Ren
Journal:  Theranostics       Date:  2019-08-14       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.